One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Germany Diabetes Care Devices Market

[ 英語タイトル ] Germany Diabetes Care Devices Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0087977
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 90
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD3250 / Question Form
5 User USD3750 / Question Form
Enterprise User USD6500 / Question Form
 - Abbott Diabetes Care
- Roche
- Johnson & Johnson
- Dexcom
- Medtronic
- Ascensia Diabetes Care
- AgaMatrix
- Bionime Corporation
- Novo Nordisk
- Eli Lilly
- Sanofi
- Rossmax International Ltd

[Report Description]

In the European diabetes care devices market, Germany accounted for approximately 21.9% of the total market value in 2019. The diabetes care device market in Germany is expected to register a CAGR of more than 8% during the forecast period. Germany is one of the developed countries and advanced in terms of healthcare facilities. Technologies, such as continuous glucose monitoring and insulin infusion pumps, are getting adopted rapidly in Germany than the other developing countries. Moreover, the reimbursement policy and the pricing policy are highly regulated, which drive the market and increase the adoption rate of new and advanced technologies. The roll-out of many new drugs, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among the people are some of the market opportunities for the players in the German diabetes care device market.

Key Market Trends

The Monitoring Devices Segment Occupied the Highest Market Share in the German Diabetes Care Devices Market in 2019

Monitoring devices include self-monitoring blood glucose devices (SMBG) and continuous glucose monitoring devices (CGM), where SMBG devices held the highest share in 2019, with a revenue of USD 0.9 billion. The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients need to check their blood glucose levels at regular intervals, in order to monitor their blood glucose levels and adjust the insulin dosing accordingly. Therefore, if a patient performs 5-6 tests in a day, the average expenditure on test strips may be more than USD 100/month. These expenses add to the already high costs of diabetes management, and they are impeding market growth. The current CGM devices show a detailed representation of blood glucose patterns and tendencies compared to a routine check of glucose levels at set intervals.

Disposable Insulin Pens Hold the Highest Market Share Among Insulin Delivery Devices

Insulin disposable pens are the most widely used devices for the administration of insulin in Germany. This sub-segment occupies more than 55% of the share in the management devices segment and around 13% of the market share in the whole diabetes care devices market. Insulin cartridges in reusable pens are known to be a needed extension to insulin pens. These devices are considered to be an upgraded version of the insulin vials. Most types of insulins are manufactured in the form of cartridges, thus, making it easily accessible.​ These devices have all the functional benefits of reusable pens and are cost-effective, as these cartridges are less expensive compared to disposable insulin pens. ​Due to the increasing demand for insulin cartridges, most of the insulin device manufacturing companies have produced reusable insulin pens that are compatible with various insulin manufacturers' cartridges.​ These insulin cartridges are considered to be more socially friendly, as they are smaller and less noticeable than the classic vial-and-syringe. They are also more portable for consumers on-the-go. ​Cartridges that are open do not need to be refrigerated, thus, making the storage very easy for consumers. Therefore, using cartridges is the most cost-effective way to use insulin, as reusable pens are a one-time investment, unlike disposable pens. ​

Competitive Landscape

There have been constant innovations driven by manufacturers to compete in the market. The major players, such as Abbott and Medtronic, have undergone many mergers, acquisitions, and partnerships to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. The manufacturers of insulin delivery devices are spending a massive amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may help enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible with the FreeStyle Libre portfolio of products.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5 Market Segmentation
5.1 By Product
5.1.1 By Monitoring Devices (Value and Volume 2012-2025) Self-monitoring Blood Glucose Devices Glucometer Devices Blood Glucose Test Strips Lancets Continuous Glucose Monitoring Sensors Durables
5.1.2 By Management Devices (Value and Volume 2012-2025) Insulin Pump Insulin Pump Device Insulin Pump Reservoir Infusion Set Insulin Syringes Cartridges in Reusable pens Insulin Disposable Pens Jet Injectors

6.1 Type-1 Diabetes Population (2012-2025)
6.2 Type-2 Diabetes Population (2012-2025)

7.1 Company Profiles
7.1.1 Abbott Diabetes Care
7.1.2 Roche
7.1.3 Johnson & Johnson
7.1.4 Dexcom
7.1.5 Medtronic
7.1.6 ARKRAY Inc.
7.1.7 Ascensia Diabetes Care
7.1.8 AgaMatrix
7.1.9 Bionime Corporation
7.1.10 Novo Nordisk
7.1.11 Eli Lilly
7.1.12 Sanofi
7.1.13 Rossmax International Ltd




Recommended reports